<rst>
<header>
	<relations>
			<rel name="elaboration" type="rst"/>
			<rel name="means" type="rst"/>
			<rel name="attribution" type="rst"/>
			<rel name="concession" type="rst"/>
			<rel name="purpose" type="rst"/>
			<rel name="preparation" type="rst"/>
			<rel name="same_unit" type="multinuc"/>
			<rel name="contrast" type="multinuc"/>
			<rel name="joint" type="multinuc"/>
		</relations>
</header>
<body>
<segment id="1" parent="1001" relname="preparation">1. Introduction</segment>
<segment id="2" parent="1002" relname="span">Eosinophils are a subset of granulocytes mostly known for their capacity</segment>
<segment id="3" parent="1003" relname="joint">to stimulate allergic reactions</segment>
<segment id="4" parent="1003" relname="joint">and to fight parasites .</segment>
<segment id="5" parent="1006" relname="joint">Under normal conditions , these cells are relatively rare</segment>
<segment id="6" parent="1006" relname="joint">representing 1 – 3 % of total white blood cells .</segment>
<segment id="7" parent="1009" relname="span">During certain inflammatory conditions</segment>
<segment id="8" parent="7" relname="elaboration">( i. e. , allergies , parasitic infections , autoimmune diseases )</segment>
<segment id="9" parent="1008" relname="same_unit">eosinophils can rapidly increase ,</segment>
<segment id="10" parent="1010" relname="joint">due to both de novo generation from bone marrow precursors and proliferation of tissue-resident cells ,</segment>
<segment id="11" parent="1010" relname="joint">infiltrating inflamed tissues , including tumors .</segment>
<segment id="12" parent="1012" relname="span">Tumor-associated tissue eosinophilia has been described in various solid tumors</segment>
<segment id="13" parent="12" relname="concession">although its prognostic value in clinical oncology remains controversial .</segment>
<segment id="14" parent="1014" relname="joint">In vivo , eosinophils were shown to exert a protective role inhibiting tumor growth in mouse models of melanoma , colorectal cancer , hepatocellular carcinoma , and inducible fibrosarcoma .</segment>
<segment id="15" parent="1015" relname="joint">Furthermore , eosinophils infiltration in the lung can prevent the formation of experimental pulmonary metastasis .</segment>
<segment id="16" parent="1017" relname="span">Eosinophils are equipped with granules</segment>
<segment id="17" parent="1018" relname="span">carrying a plethora of cytotoxic mediators , such as the cationic proteins major basic protein</segment>
<segment id="18" parent="17" relname="elaboration">( MBP ) ,</segment>
<segment id="19" parent="1020" relname="span">eosinophil cationic protein</segment>
<segment id="20" parent="19" relname="elaboration">( ECP ) ,</segment>
<segment id="21" parent="1022" relname="span">eosinophil peroxidase</segment>
<segment id="22" parent="21" relname="elaboration">( EPX ) ,</segment>
<segment id="23" parent="1023" relname="span">and granzymes</segment>
<segment id="24" parent="1024" relname="span">( granzyme-A in human cells , granzyme-B in murine cells )</segment>
<segment id="25" parent="24" relname="elaboration">that can destroy target cells or tissues .</segment>
<segment id="26" parent="1026" relname="span">Indeed , eosinophils were shown to directly kill human colon carcinoma cells via release of granzyme-A in a mechanism</segment>
<segment id="27" parent="26" relname="elaboration">dependent on the integrin CD11a/CD18 and on the cytokine IL-18 .</segment>
<segment id="28" parent="1028" relname="span">In addition , eosinophils</segment>
<segment id="29" parent="28" relname="elaboration">activated by cross-linking of the receptor 2B4/CD244 exhibited tumoricidal activities against human B lymphoma cells .</segment>
<segment id="30" parent="31" relname="attribution">It appears</segment>
<segment id="31" parent="1030" relname="span">that the process of adhesion through integrins is important for eosinophil activation during inflammation .</segment>
<segment id="32" parent="1031" relname="joint">However , it is unclear whether cell adhesion and degranulation are sequential or independent events .</segment>
<segment id="33" parent="1035" relname="span">In addition , the mechanisms of granule protein secretion</segment>
<segment id="34" parent="33" relname="elaboration">( i. e. , degranulation )</segment>
<segment id="35" parent="1034" relname="same_unit">in eosinophils</segment>
<segment id="36" parent="1034" relname="elaboration">leading to tumor cytotoxicity remain to be defined .</segment>
<segment id="37" parent="1037" relname="span">IL-33 is an epithelial-derived “ alarmin ”</segment>
<segment id="38" parent="1038" relname="joint">playing multiple functions in Th2-related immunopathologies</segment>
<segment id="39" parent="1039" relname="span">and recently implied in cancer immunity ,</segment>
<segment id="40" parent="1040" relname="span">exerting pro- or anti-tumoral activities ,</segment>
<segment id="41" parent="40" relname="elaboration">depending on the tumor type and microenvironmental factors .</segment>
<segment id="42" parent="1042" relname="preparation">Tumor over-expression or exogenous administration of IL-33 promotes anti-tumor immune responses in vivo in models of melanoma , acute myeloid leukemia , lung and colorectal cancer .</segment>
<segment id="43" parent="1043" relname="span">IL-33 drives substantial recruitment of eosinophils to inflamed sites , such as the lung ,</segment>
<segment id="44" parent="1044" relname="span">likely</segment>
<segment id="45" parent="44" relname="means">by promoting eosinophilopoiesis in the bone marrow .</segment>
<segment id="46" parent="1046" relname="joint">In addition , IL-33 can induce eosinophil superoxide anion production</segment>
<segment id="47" parent="1046" relname="joint">and promote the survival of eosinophils .</segment>
<segment id="48" parent="49" relname="attribution">We initially reported</segment>
<segment id="49" parent="1048" relname="span">that IL-33 inhibits tumor growth and pulmonary metastasis in vivo in an eosinophil-dependent manner .</segment>
<segment id="50" parent="1049" relname="joint">Subsequent studies confirmed eosinophil-mediated anti-tumoral effects of IL-33 in pre-clinical models of metastatic peritoneal cancer , hepatocellular , and prostatic cancer .</segment>
<segment id="51" parent="1052" relname="attribution">Our study suggested</segment>
<segment id="52" parent="1053" relname="span">that eosinophils</segment>
<segment id="53" parent="52" relname="elaboration">recruited by IL-33 might either function as accessory cells</segment>
<segment id="54" parent="1054" relname="contrast">attracting CD8 T cells</segment>
<segment id="55" parent="1054" relname="contrast">or play a direct antitumor role .</segment>
<segment id="56" parent="1057" relname="span">Here , we further investigated the anti-tumoral mechanisms</segment>
<segment id="57" parent="56" relname="elaboration">operated by eosinophils</segment>
<segment id="58" parent="1057" relname="elaboration">following activation with IL-33 .</segment>
<segment id="59" parent="60" relname="attribution">By using a panel of tumor cell lines , we show</segment>
<segment id="60" parent="1059" relname="span">that IL-33 promotes tumoricidal functions of eosinophils in vitro and in vivo in a cell adhesion-dependent manner , through the integrin CD11b/CD18 and by inducing lytic granule convergence to the immune synapse .</segment>
<segment id="61" parent="1060" relname="span">Our data provide mechanistic insights into eosinophil anti-tumor activities</segment>
<segment id="62" parent="1061" relname="span">stimulated by IL-33</segment>
<segment id="63" parent="1062" relname="span">that involve cell contact and directional secretion of granules toward target tumor cells</segment>
<segment id="64" parent="63" relname="elaboration">enhancing killing efficiency .</segment>
<group id="1000" type="span" />
<group id="1001" type="span" parent="1000" relname="span"/>
<group id="1002" type="span" parent="1001" relname="span"/>
<group id="1003" type="multinuc" parent="2" relname="purpose"/>
<group id="1004" type="multinuc" parent="1002" relname="elaboration"/>
<group id="1005" type="multinuc" parent="1004" relname="joint"/>
<group id="1006" type="multinuc" parent="1005" relname="joint"/>
<group id="1007" type="multinuc" parent="1005" relname="joint"/>
<group id="1008" type="multinuc" parent="1007" relname="same_unit"/>
<group id="1009" type="span" parent="1008" relname="same_unit"/>
<group id="1010" type="multinuc" parent="1007" relname="same_unit"/>
<group id="1011" type="multinuc" parent="1004" relname="joint"/>
<group id="1012" type="span" parent="1011" relname="joint"/>
<group id="1013" type="multinuc" parent="1011" relname="joint"/>
<group id="1014" type="multinuc" parent="1013" relname="joint"/>
<group id="1015" type="multinuc" parent="1014" relname="joint"/>
<group id="1016" type="multinuc" parent="1015" relname="joint"/>
<group id="1017" type="span" parent="1016" relname="same_unit"/>
<group id="1018" type="span" parent="16" relname="elaboration"/>
<group id="1019" type="multinuc" parent="1016" relname="same_unit"/>
<group id="1020" type="span" parent="1019" relname="same_unit"/>
<group id="1021" type="multinuc" parent="1019" relname="same_unit"/>
<group id="1022" type="span" parent="1021" relname="joint"/>
<group id="1023" type="span" parent="1021" relname="joint"/>
<group id="1024" type="span" parent="23" relname="elaboration"/>
<group id="1025" type="multinuc" parent="1013" relname="joint"/>
<group id="1026" type="span" parent="1025" relname="joint"/>
<group id="1027" type="multinuc" parent="1025" relname="joint"/>
<group id="1028" type="span" parent="1027" relname="joint"/>
<group id="1029" type="span" parent="1027" relname="joint"/>
<group id="1030" type="span" parent="1031" relname="concession"/>
<group id="1031" type="multinuc" parent="1029" relname="span"/>
<group id="1032" type="multinuc" parent="1031" relname="joint"/>
<group id="1033" type="span" parent="1032" relname="joint"/>
<group id="1034" type="multinuc" parent="1033" relname="span"/>
<group id="1035" type="span" parent="1034" relname="same_unit"/>
<group id="1036" type="multinuc" parent="1032" relname="joint"/>
<group id="1037" type="span" parent="1036" relname="joint"/>
<group id="1038" type="multinuc" parent="37" relname="elaboration"/>
<group id="1039" type="span" parent="1038" relname="joint"/>
<group id="1040" type="span" parent="39" relname="elaboration"/>
<group id="1041" type="span" parent="1036" relname="joint"/>
<group id="1042" type="multinuc" parent="1041" relname="span"/>
<group id="1043" type="span" parent="1042" relname="joint"/>
<group id="1044" type="span" parent="43" relname="elaboration"/>
<group id="1045" type="multinuc" parent="1042" relname="joint"/>
<group id="1046" type="multinuc" parent="1045" relname="joint"/>
<group id="1047" type="multinuc" parent="1045" relname="joint"/>
<group id="1048" type="span" parent="1047" relname="joint"/>
<group id="1049" type="multinuc" parent="1047" relname="joint"/>
<group id="1050" type="multinuc" parent="1049" relname="joint"/>
<group id="1051" type="span" parent="1050" relname="joint"/>
<group id="1052" type="span" parent="1051" relname="span"/>
<group id="1053" type="span" parent="1052" relname="span"/>
<group id="1054" type="multinuc" parent="1053" relname="elaboration"/>
<group id="1055" type="span" parent="1050" relname="joint"/>
<group id="1056" type="span" parent="1058" relname="preparation"/>
<group id="1057" type="span" parent="1056" relname="span"/>
<group id="1058" type="multinuc" parent="1055" relname="span"/>
<group id="1059" type="span" parent="1058" relname="joint"/>
<group id="1060" type="span" parent="1058" relname="joint"/>
<group id="1061" type="span" parent="61" relname="elaboration"/>
<group id="1062" type="span" parent="62" relname="elaboration"/>
	</body>
</rst>
